Compare Stocks

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Deutsche Wohnen SE develops and manages residential properties in Germany. The company operates through Rental, Value-add, Recurring Sales, Development, and Care segment. The Rental segment offers value-enhancing management to residential real estate portfolio. The Value- add segment engages in the core business of letting. This segment also includes multimedia services and the supply of energy. The Recurring Sales segment includes sales of individual condominiums and single-family homes. The Development segment includes project development to create new living space. The care segment includes all activities related to the management of care facilities and the leasing of care properties. Deutsche Wohnen SE was founded in 1924 and is headquartered in Berlin, Germany. Deutsche Wohnen SE operates as a subsidiary of Vonovia SE.

Ferrovial SE, together with its subsidiaries, develops transport infrastructure, mobility solutions, civil works, and buildings projects in Spain and internationally. The company designs and builds various public and private works; and develops, finances, and operates toll roads. Its construction activities include highways, tunnels, bridges, and airports; designs, constructs, operates and maintains potable water treatment plants, urban and industrial waste water treatment plants, and desalination plants. In addition, the company manufactures and markets asphalt and bitumen products; develops, operates, and manages airports; and promotes, constructs, and operates energy generation and transmission infrastructures. Further, it provides mobility services, include ZITY, an electric carsharing service application; invests in electric vehicle sector, including cars and associated charging infrastructures; and sells, rents, and maintains hydraulic equipment, jacks, and floating caisson equipment. The company was founded in 1952 and is based in Madrid, Spain.

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Surgutneftegas PJSC engages in the research and design, exploration, drilling and production units, oil refining, gas processing, and marketing subsidiaries. The firm is involved in activities, which include exploration and production of oil and gas provinces, such as Western Siberia, Eastern Siberia, and Timan-Pechora; oil refining; and gas production and transportation. It also focuses on wholesaling, retailing and storage of petroleum products and render a set of supplementary services at the gas stations. The company was founded in 1964 and is headquartered in Surgut, Russia.